Tagged with Oncology

France Abbvie France’s Pierre-Claude Fumoleau outlines his strategic priorities for the affiliate, AbbVie’s unique corporate culture and ethos, and how he envisions upcoming regulatory reforms playing out in France.   We are still a very young company… and that means that we are still very much in the process of constructing…

China Terns Pharmaceuticals is developing innovative drugs for the treatment of NASH and liver disease. It has established a diverse product pipeline with drug candidates targeting different stages of the disease and with complementary mechanisms of action, through partnerships with global pharma companies as well as in-house discovery efforts. With offices…

Switzerland Roche announced strong Group sales growth of seven percent for 2018, partly driven by the launch of MS blockbuster Ocrevus, which CEO Severin Schwan has described as the most successful in the company’s history.   2018 was a good year for Roche. The Swiss-headquartered pharma giant saw seven percent overall…

China Dr Xu Ting, founder, chairman and CEO of Alphamab Oncology, shares his expert opinion on the recent regulatory and healthcare reforms in China, the expertise Alphamab Oncology has in protein engineering and their mission to become a highly differentiated oncology biotech company, and Alphamab’s dual China-US development strategy in support…

Korea Kyoung-June Lee, CEO of JW CreaGene, lifts the lid on their novel technology of developing an immuno-oncology treatment from dendritic cells, which act as a command centre of the immune system in the body. He also assesses how this new treatment will compare to existing technologies, such as CAR-T.  …

China Dr Wang Yinxiang, chairman; and Dr Hu Shaojing, President (R&D); of Jacobio Pharmaceutical; share the exciting story behind Jacobio’s establishment in 2015, their ambition to become a global biopharma player with the plan of launching at least one IND every year and to open a research lab in Boston; and…

France Frédéric Collet, president Novartis France and general manager oncology explains the rationale behind Novartis’s consistent investment in France, the current shift in the company’s corporate culture and the main challenges inherent to the unprecedented wave of innovation that is revolutionizing the health industry.   In terms of research, we have invested EUR…

Korea Shingyu Bae, CEO of MDimune, explains how the company’s new exosome drug delivery system increases efficacy and reduces toxicity compared with other oncology products. He also discusses the potential and attractiveness of the Korean biotech industry as a global leader in developing new technologies.   Our vision is to give…

Spain Ruth Vera highlights how the Spanish Society of Medical Oncology (SEOM) works to be the premier partner in the Spanish oncology ecosystem and the main cancer problems Spain is currently experiencing. Furthermore, she suggests how Spain can improve its oncology care and her aspirations for the future.   As in…

France Professor Alexander Eggermont, general director of Gustave Roussy, gives insights into the transformation of the Hospital under his ten-year leadership mandate. He also explains the rationale behind creating Cancer Core Europe, a collaborative platform of Europe’s seven leading cancer institutes.   Our system brings between 3500 and 4000 patients into…

Korea National OncoVenture (NOV) is Korea’s Ministry of Health and Welfare funded oncology drug development program to nurture oncology innovation in the country. To maintain high access and limit costs of oncology therapies, we still need to assist in the development of local Korean biotech companies. — Young-Whan Park, President of National…

Malaysia Dr. Saunthari Somasundaram walks us through the NCSM’s mission to raise awareness on cancer prevention and early diagnosis in Malaysia. She details the need for more government support to make cancer education a pillar in healthcare and discredits the idea that care only includes treatment and cure.   Could you…